The Tempo Team
Westbrook Weaver, PhD
Founder, Director, & CEO
A co-inventor of Tempo's core material technology during his post-doctoral work in Biomedical Engineering at UCLA, Westbrook leads operations and strategy at Tempo.
Donald Griffin, PhD
Founder, Director, & CSO
A co-inventor of Tempo's technology, Don's is a leader in biomaterials research and tissue engineering with over 10 years experience. He directs Tempo scientific operations.
Stephanie Deshayes, PhD
With over 10 years of experience in biomaterial Science, organic synthesis, and drug delivery development. Stephanie drives technology development and scientific operations at Tempo.
Associate Director of Product Development
Sam has 10 years of experience in the complex biologics realm - from manufacturing to process development, quality, and regulatory compliance. He leads Tempo's development and regulatory strategy.
Philip Scumpia, MD PhD
Founder & Clinical Advisor
Dr. Scumpia is a leading Immunologist and practicing dermatologist at UCLA and the Veterans Administration with deep experience in the medical dermatology, wound care, and cosmetic spheres. He is a co-inventor on Tempo’s technology, and advises in Tempo's clinical development.
Tempo's Board of Directors
Rick has over 35 years of experience in biotechnology management where he has built global marketing and sales campaigns, structured and executed large contracts, licensing, partnerships, brought in significant venture investment, and taken companies through acquisition. Rick is crucial for Tempo’s business development strategy and corporate operations.
Dino Di Carlo, PhD
Dino is a co-founder and co-inventor of Tempo's technology, He is the vice-chair of Bioengineering at UCLA, with 100+ peer reviewed journal articles and 20+ patents. He is also an experienced biotechnology entrepreneur, with two venture-backed companies. Dino plays a critical role in Tempo's early development.
Steven Richieri, MBA
Steve has over 30 years of experience in the biotechnology and medical device arena. He has founded 4 successful companies where he served various executive roles including CEO and COO. He has regulatory experience, with 22 approved FDA submissions including 510(k), De Novo, and PMA mechanisms. Steve helps direct Tempo’s business development and regulatory execution.